New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 31, 2012
12:34 EDTHLF, PFE, CG, BMY, CALM, DUFOn The Fly: Midday Wrap
Stocks on Wall Street were mixed at midday as the last minute fiscal cliff negotiations may prove to be a boost, or a bane, to the averages in the last hours of trading of the year. With little else for investors to key in on, the fiscal cliff headlines will dominate once again for the remainder of the session... ECONOMIC EVENTS: In the U.S. a minor economic report, the Dallas Fed's December manufacturing survey, came in better than expected at +6.8. In China, the HSBC purchasing managers’ index for December rose to a final reading of 51.5, an upward revision from the preliminary 50.9 result and an improvement from 50.5 a month earlier... COMPANY NEWS: After Friday's closing bell, the FDA announced it had approved the anti-clotting drug Eliquis, marketed by Bristol-Myers Squibb (BMY) and Pfizer (PFE). Atlantic Equities upgraded Bristol-Myers citing the approval and shares advanced about 1%. Pfizer shares, however, slid about 0.3%... MAJOR MOVERS: Among the notable gainers was Duff & Phelps (DUF), up 20% after agreeing to be acquired by a group led by The Carlyle Group (CG), with the provision that Duff & Phelps can continue to seek a better deal. Also higher were shares of Herbalife (HLF), which rose over 8% as the stock continues to bounce back from the sell-off begun with Bill Ackman's revelation of his short position. Among the noteworthy losers was Cal-Maine Foods (CALM), down 10% after reporting Q2 earnings that missed expectations... INDICES: Near noon, the Dow was down 2.10, or 0.02%, to 12,936.01; the Nasdaq was up 20.07, or 0.68%, to 2,980.38; and the S&P 500 was up 3.80, or 0.27%, to 1,406.23.
News For BMY;PFE;DUF;CG;HLF;CALM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 14, 2015
13:28 EDTCALMIncreasing equity options volume
Increasing equity options volume: FCX UPS KSS CHK CSCO AVP YOKU CALM KORS
12:29 EDTPFEPfizer receives 'second request' from FTC regarding potential Hospira merger
Subscribe for More Information
11:03 EDTBMYBristol-Myers treatment of progressive supranuclear palsy granted orphan status
Subscribe for More Information
10:41 EDTBMYAnalysts upbeat on Amgen's Kyprolis after ASCO abstracts
Subscribe for More Information
09:22 EDTBMYLeerink pharma/biotech analysts hold an analyst/industry conference call
Subscribe for More Information
09:09 EDTBMYBristol-Myers down 1.3% after release of ASCO abstracts
Subscribe for More Information
08:39 EDTPFETargacept, Catalyst Biosciences amend definitive merger agreement
Subscribe for More Information
08:08 EDTPFEPfizer director Marc Tessier-Lavigne to step down from board
Subscribe for More Information
06:49 EDTCALMCal-Maine Foods volatility as shares at record high on avian influenza
Subscribe for More Information
May 13, 2015
19:17 EDTPFEHospira and FDA detect security vulnerabilities in infusion pumps
Subscribe for More Information
17:19 EDTPFEPfizer, Merck KGaA to present data at ASCO for avelumab
Subscribe for More Information
13:43 EDTPFEHospira shareholders approve merger with Pfizer
Hospira (HSP) announced that Hospira shareholders voted in favor of the proposal to adopt the merger agreement with Pfizer (PFE) at a special meeting of stockholders held May 13 in Denver, Colorado. On February 5, Hospira and Pfizer announced they had entered into a merger agreement under which Pfizer will acquire Hospira for $90 per share in cash for a total enterprise value of approximately $17B. The merger is subject to customary closing conditions, one of which was approval of the merger by Hospira's shareholders. Additional closing conditions to be met include obtaining regulatory approvals in several jurisdictions. Hospira and Pfizer continue to expect the merger to close in the second half of 2015.
13:12 EDTBMYSen. Sanders urges VA to break patents on Gilead hepatitis C drugs
Subscribe for More Information
07:31 EDTPFEHeart Rhythm Society to hold a conference
Heart Rhythm 2015 is being held in Boston on May 13-16.
May 12, 2015
18:47 EDTHLFCasino union requests Herbalife investigation, Reuters says
Subscribe for More Information
May 11, 2015
17:36 EDTPFEAthersys down 10.1% after Pfizer notified that it will terminate agreement
Subscribe for More Information
17:34 EDTPFEAthersys receives notification that Pfizer will terminate agreement
Subscribe for More Information
16:33 EDTPFEPfizer takes minority interest in AM-Pharma, secures option to acquire company
AM-Pharma and Pfizer announced that Pfizer has acquired a minority equity interest in AM-Pharma and secured an exclusive option to acquire the remaining equity in the company. The option becomes exercisable upon completion of a Phase II trial of recAP in the treatment of Acute Kidney Injury related to sepsis. There are no drugs currently approved for this condition and the only treatment option is dialysis and supportive care. Results from the current Phase II trial for recAP are expected in the second half of 2016. Under the terms of the agreement, Pfizer has made an upfront payment of $87.5M for the minority equity interest and exclusive option, with additional potential payments of up to $512.5M upon option exercise and potential launch of any product that may result from this agreement. Other terms of the transaction were not disclosed. “Pfizer is committed to advancing the science to address the high unmet medical need in Acute Kidney Injury,” said Mikael Dolsten, M.D., Ph.D., president, Worldwide Research and Development at Pfizer. “Clinical data for recAP show the potential to uniquely address Acute Kidney Injury in the setting of sepsis, and we look forward to working with our partners at AM-Pharma as we aim to accelerate the development of recAP into a potential first-in-class treatment for patients.”
10:34 EDTCALMCal-Maine Foods price target raised to $67 from $51 at Sidoti
Sidoti raised Buy rated Cal-Maine Foods' price target to $67 from $51 and increased estimates to reflect egg pricing power. The firm said avian influenza has resulted in nearly 28M layers being quarantined, which will take 20 to 24 months to repopulate. Sidoti views this as an opportunity for Cal-Maine to enhance its higher-margin, egg breaking operation and raised its 2016 EPS estimate to $2 from $1.09 and 2017 EPS to $1.75 from $1.05.
09:02 EDTCGComcast names Michael Cavanagh as CFO
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use